Logo image of TSVT

2SEVENTY BIO INC (TSVT) Stock Fundamental Analysis

NASDAQ:TSVT - Nasdaq - US9013841070 - Common Stock - Currency: USD

5  +0.01 (+0.2%)

After market: 5 0 (0%)

Fundamental Rating

3

Overall TSVT gets a fundamental rating of 3 out of 10. We evaluated TSVT against 551 industry peers in the Biotechnology industry. TSVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TSVT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TSVT has reported negative net income.
TSVT had a negative operating cash flow in the past year.
In the past 5 years TSVT always reported negative net income.
In the past 5 years TSVT always reported negative operating cash flow.
TSVT Yearly Net Income VS EBIT VS OCF VS FCFTSVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

TSVT has a better Return On Assets (-11.94%) than 83.81% of its industry peers.
TSVT has a better Return On Equity (-27.16%) than 79.54% of its industry peers.
Industry RankSector Rank
ROA -11.94%
ROE -27.16%
ROIC N/A
ROA(3y)-29.71%
ROA(5y)-33.2%
ROE(3y)-64.75%
ROE(5y)-87.29%
ROIC(3y)N/A
ROIC(5y)N/A
TSVT Yearly ROA, ROE, ROICTSVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

TSVT has a better Gross Margin (52.43%) than 77.22% of its industry peers.
In the last couple of years the Gross Margin of TSVT has declined.
The Profit Margin and Operating Margin are not available for TSVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.09%
GM growth 5Y-10.87%
TSVT Yearly Profit, Operating, Gross MarginsTSVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

TSVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
TSVT has more shares outstanding than it did 1 year ago.
TSVT has more shares outstanding than it did 5 years ago.
TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TSVT Yearly Shares OutstandingTSVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TSVT Yearly Total Debt VS Total AssetsTSVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -1.30, we must say that TSVT is in the distress zone and has some risk of bankruptcy.
TSVT's Altman-Z score of -1.30 is in line compared to the rest of the industry. TSVT outperforms 59.07% of its industry peers.
TSVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.3
ROIC/WACCN/A
WACC10.02%
TSVT Yearly LT Debt VS Equity VS FCFTSVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M

2.3 Liquidity

TSVT has a Current Ratio of 4.67. This indicates that TSVT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TSVT (4.67) is comparable to the rest of the industry.
A Quick Ratio of 4.67 indicates that TSVT has no problem at all paying its short term obligations.
TSVT has a Quick ratio (4.67) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.67
Quick Ratio 4.67
TSVT Yearly Current Assets VS Current LiabilitesTSVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

TSVT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.14%, which is quite impressive.
The Revenue for TSVT has decreased by -62.28% in the past year. This is quite bad
TSVT shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.09% yearly.
EPS 1Y (TTM)72.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-62.28%
Revenue growth 3Y-11.43%
Revenue growth 5Y-3.09%
Sales Q2Q%84.29%

3.2 Future

TSVT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.56% yearly.
Based on estimates for the next years, TSVT will show a quite strong growth in Revenue. The Revenue will grow by 12.75% on average per year.
EPS Next Y58.41%
EPS Next 2Y33.7%
EPS Next 3Y30.96%
EPS Next 5Y20.56%
Revenue Next Year42.31%
Revenue Next 2Y24.94%
Revenue Next 3Y18.14%
Revenue Next 5Y12.75%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TSVT Yearly Revenue VS EstimatesTSVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
TSVT Yearly EPS VS EstimatesTSVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TSVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TSVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSVT Price Earnings VS Forward Price EarningsTSVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSVT Per share dataTSVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as TSVT's earnings are expected to grow with 30.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.7%
EPS Next 3Y30.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TSVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

2SEVENTY BIO INC

NASDAQ:TSVT (5/12/2025, 8:00:01 PM)

After market: 5 0 (0%)

5

+0.01 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners89.58%
Inst Owner Change-3.55%
Ins Owners4.73%
Ins Owner Change-1890.49%
Market Cap266.15M
Analysts47.5
Price Target5.1 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.06%
Min EPS beat(2)-36.88%
Max EPS beat(2)22.77%
EPS beat(4)2
Avg EPS beat(4)33.02%
Min EPS beat(4)-36.88%
Max EPS beat(4)168.1%
EPS beat(8)5
Avg EPS beat(8)20.21%
EPS beat(12)8
Avg EPS beat(12)15.79%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-44.21%
Min Revenue beat(2)-76.66%
Max Revenue beat(2)-11.76%
Revenue beat(4)0
Avg Revenue beat(4)-34.98%
Min Revenue beat(4)-76.66%
Max Revenue beat(4)-11.76%
Revenue beat(8)1
Avg Revenue beat(8)-19.01%
Revenue beat(12)3
Avg Revenue beat(12)2.13%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-23.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.4%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.03
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.71
BVpS3.96
TBVpS3.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.94%
ROE -27.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.43%
FCFM N/A
ROA(3y)-29.71%
ROA(5y)-33.2%
ROE(3y)-64.75%
ROE(5y)-87.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.09%
GM growth 5Y-10.87%
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.96%
Cap/Sales 1.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.67
Quick Ratio 4.67
Altman-Z -1.3
F-Score3
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)114.29%
Cap/Depr(5y)126.28%
Cap/Sales(3y)13.55%
Cap/Sales(5y)17.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y58.41%
EPS Next 2Y33.7%
EPS Next 3Y30.96%
EPS Next 5Y20.56%
Revenue 1Y (TTM)-62.28%
Revenue growth 3Y-11.43%
Revenue growth 5Y-3.09%
Sales Q2Q%84.29%
Revenue Next Year42.31%
Revenue Next 2Y24.94%
Revenue Next 3Y18.14%
Revenue Next 5Y12.75%
EBIT growth 1Y54.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.95%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.06%
OCF growth 3YN/A
OCF growth 5YN/A